Parkinson's disease (PD) is one of many neurodegenerative diseases termed synucleinopathies, neuropathologically defined by inclusions containing aggregated a-synuclein (aS). aS gene (SNCA) mutations can directly cause autosomal dominant PD. In vitro studies demonstrated that SNCA missense mutations may either enhance or diminish aS aggregation but cross-seeding of mutant and wild-type aS proteins appear to reduce aggregation efficiency. Here, we extended these studies by assessing the effects of seeded aS aggregation in aS transgenic mice through intracerebral or peripheral injection of various mutant aS fibrils. We observed modestly decreased time to paralysis in mice transgenic for human A53T aS (line M83) intramuscularly injected with H50Q, G51D or A53E aS fibrils relative to wild-type aS fibrils. Conversely, E46K aS fibril seeding was significantly delayed and less efficient in the same experimental paradigm. However, the amount and distribution of aS inclusions in the central nervous system were similar for all aS fibril muscle injected mice that developed paralysis. Mice transgenic for human aS (line M20) injected in the hippocampus with wild-type, H50Q, G51D or A53E aS fibrils displayed induction of aS inclusion pathology that increased and spread over time. By comparison, induction of aS aggregation following the intrahippocampal injection of E46K aS fibrils in M20 mice was much less efficient. These findings show that H50Q, G51D or A53E can efficiently cross-seed and induce aS pathology in vivo. In contrast, E46K aS fibrils are intrinsically inefficient at seeding aS inclusion pathology. Consistent with previous in vitro studies, E46K aS polymers are likely distinct aggregated conformers that may represent a unique prion-like strain of aS.
Introduction
Alterations of the SNCA gene, either owing to increased copy number of the entire gene or missense mutations within the Nterminal region of the encoded protein, are a known cause of autosomal dominant Parkinson's disease (PD; OMIM # 605543 and 168601, respectively) or the related disorder dementia with Lewy bodies (DLB; OMIM # 127750) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . SNCA encodes the 140 amino acid lipid-binding protein, a-synuclein (aS), which is predominantly presynaptic (11) . The natively unstructured aS can adopt an a-helical conformation, via imperfect KTKEGV repeats in its N-terminal region, allowing it to bind to lipids (12) . However, aS may misfold into the b-pleated sheet structure, known as amyloid, which is aggregate prone. This form of aS polymerizes into fibrillar structures that coalesce to form pathological inclusions which are a hallmark of a class of neurodegenerative diseases termed synucleinopathies (13) (14) (15) (16) . Synucleinopathies include PD, DLB and multiple system atrophy (MSA; OMIM # 146500), but aS pathology may also occur in a subset of other neurodegenerative disorders including Alzheimer's disease (OMIM # 104310) (13) (14) (15) (16) (17) (18) (19) (20) .
In vitro, the H50Q and A53T aS mutations were shown to accelerate (21) (22) (23) (24) (25) (26) (27) , whereas G51D and A53E aS mutations slow down aggregation of aS compared with the wild-type protein (26) (27) (28) (29) (30) . The effects of the A30P and the E46K aS mutations on in vitro aggregation have also been investigated, but reports have displayed conflicting results as to whether they accelerate (25, (31) (32) (33) (34) (35) or decelerate aS aggregation (27, 36, 37) .
The polymerization of aS into amyloid fibrils is nucleation dependent (38) and the in vivo aggregation of endogenous aS can be induced by the introduction of preformed aS amyloidogenic seeds by a prion-like conformation templating mechanism (39) (40) (41) (42) . Owing to the autosomal dominant nature of the SNCA missense mutations patients carry one wild-type allele, yielding a situation where cross-seeding events between mutant and wild-type proteins likely occur. The effects of such cross-seeding have predominantly been studied in vitro (27, 34) . Dhavale et al. showed that mutant fibrils can induce the aggregation of wild-type aS, however, the rate at which this occurs is significantly reduced compared with homologous seeding (27) . Nonetheless, the relevance of these in vitro studies to an in vivo setting and human conditions is uncertain. Herein, we aim to extend these studies into relevant models of synucleinopathy by assessing the effect of induced aS aggregation by seeding with mutant aS fibrils in aS transgenic mouse models.
Results
In the current study, we aimed to assess the relative abilities of mutant aS fibrils to induce aggregation of aS in vivo. To achieve this, we utilized two well-established seeding paradigms; injection of aS fibrils either directly into the brain, or peripherally, in aS transgenic mice (43) (44) (45) (46) . We used different lines of mice for each injection paradigm. Mice transgenic for human wild-type (M20 line) and human A53T (M83 line) aS were used for the intrahippocampal and intramuscular injections, respectively (47) . The M20 mice were used for the cerebral injections as these mice never intrinsically develop aS inclusion pathology (47) . M83 mice were used for intramuscular injection of preformed aS seeds as the subsequent induction of aS aggregation and motor impairment is much more robust in these mice, resulting in a highly reproducible behavior readout (46) . M83 mice injected bilaterally in the gastrocnemius muscle with aS fibrils were allowed to age until the presentation of motor impairment that progressed to paralysis. Some mice had to be sacrificed early owing to fight wounds and were consequently not included in the subsequent analysis (final n ¼ 6-9/ group). In this experimental paradigm, the neuronal retrograde transport of aS fibril seeds, as previously demonstrated by the significant delay or complete prevention of central nervous system (CNS) aS pathology by the prior severing of the sciatic nerve (46) , is the primary mechanism of CNS neuroinvasion, although additional transport mechanisms such as hematogenous spread also may contribute to this process.
Mice injected with wild-type aS fibrils displayed motor impairment between 126 and 168 days post-injection (Fig. 1A) . The time between injection and end-stage was similar between mice injected with H50Q, G51D and A53E aS fibrils, with all mice developing motor impairment between 100 and 135 days (Fig. 1A ). Those injected with E46K aS fibrils showed greater variability in the onset of paralysis (Fig. 1A) . One mouse displayed paralysis at 124 days post-injection, however, 6 were motor impaired much later (229-357 days post-injection) and 2 did not display any motor phenotype after injection of E46K aS fibrils, and were sacrificed for analysis at 375 days post-injection. All of the survival curves of mice injected with mutant aS fibrils were significantly different from the curve of wild-type aS fibril injected mice; H50Q, G51D and A53E curves were slightly but significantly earlier than the wild-type curve (P ¼ 0.0029, 0.0074 and 0.0008, respectively), and the E46K curve was significantly later than wild-type (P ¼ 0.0002).
Analysis of the amount and distribution of aS inclusions was assessed by immunostaining using antibody LS4-2G12, which specifically detects aS phosphorylated at serine 129 (pSer129 aS), a marker of aS inclusion pathology (Figs 1B and 2) (48). We observed similar distributions of aS pathology in all of the mice that were paralyzed, with abundant aS inclusions throughout the spinal cord, brainstem, periaqueductal gray region, midbrain and thalamus. The morphology of the aS inclusions was also similar across the different cohorts of mice, with frequent perikaryal and neuritic inclusions observed in all injection groups. Conversely, the E46K aS fibril injected mice that were sacrificed >12 months post-injection without motor impairment displayed a paucity of aS inclusions (Supplementary Material, Fig.  S1 ). The authenticity of aS inclusions was confirmed by immunostaining using our newly developed antibody 9C10 (N-terminus of aS) and the general inclusion marker, p62 ( Fig. S3 ). In addition, we showed that some of the inclusions were Thioflavin S-positive and silver stained (Supplementary Material, Fig. S4 ). As controls, we have previously shown that M83 mice injected in the muscle with immunogenic molecules including lipopolysaccharide (46) and keyhole limpet hemocyanin, or the aS-like molecule b-synuclein (49) do not induce aS aggregation or motor impairment.
For our direct brain injection study, M20 mice were bilaterally injected in the hippocampus with aS fibrils then sacrificed at either 2 or 4 months post-injection (n ¼ 4-6/group) for the wild-type, H50Q, G51D and A53E aS fibril injected mice. Owing to the latency to paralysis onset in the E46K aS fibril muscle injected mice, we decided to increase the time points of the mice injected in the hippocampus with E46K aS fibrils, and aged them for 4, 6 or 8 months post-injection (n ¼ 2-4/group). It is likely that the cycle of conformational templating of endogenous and transgenic aS by the injected amyloidogenic aS seeds followed by transport of the induced aggregated aS and subsequent conformational templating in more distally connected brain regions results in the spread of inclusion pathology in this model. However, the diffusion of aS seeds from the injection site may also contribute to the spatial induction of aS inclusion pathology. Nevertheless, even if both mechanisms are involved, this model can be used to assess the relative efficiencies of different types of aS seeds in the spatial and temporal induction of aS inclusion pathology.
At 2 months post-injection, wild-type, H50Q, G51D and A53E aS fibril injected M20 mice all displayed sparse to moderate aS pathology in the hippocampus and cortex (Figs 3A and 4A; Supplementary Material, Figs S5 and S6). Additionally, H50Q and G51D aS fibril injected M20 mice also displayed some aS inclusions in the brainstem, as well as in the thalamus of G51D injected mice. By 4 months post-injection, the amount of aS inclusion pathology had dramatically increased in all of these mice. There was robust aS pathology in the hippocampus and entorhinal cortex in each group and lower amounts in the thalamus, brainstem and spinal cord. The wild-type aS fibril injected M20 mice displayed the most aS inclusions in the cortex, while A53E aS fibril injected mice appeared to have less aS pathology overall. The morphologies of the inclusions were very similar in these cohorts of mice, with mostly neurites in areas with sparse to moderate pathology and a combination of perikaryal and neuritic inclusions in regions with more dense pathology.
Conversely, the E46K aS fibrils demonstrated very low efficiency in the induction of aS inclusion pathology in M20 mice, with only 1 out of 4 mice displaying any aS inclusions at 4 months post-injection (Figs 5 and 6; Supplementary Material, Figs S7 and S8) which were limited to the hippocampus. There was some spread of aS inclusion pathology over time, with aS inclusions identified in the thalamus and cortex in both M20 mice analyzed at the 6 month post-injection time point, however, there was a reduction in the amount of pathology observed in the hippocampus. There was further spread in the 2 M20 mice sacrificed at 8 months post-injection to the brainstem and spinal cord, and one of these mice also displayed aS inclusions in the hippocampus, cortex and thalamus whereas the other did not. Overall the amount of aS inclusions in the E46K aS fibril injected M20 mice were sparse and we observed both neuritic and perikaryal inclusions. As controls, we have previously shown that injection of phosphate buffered saline (PBS) into the cerebrum of M20 mice does not induce aS inclusion pathology (44, 50, 51) .
Discussion
In this study, we investigated the effects of seeding induced aS aggregation in aS transgenic mice by various mutant aS fibrils versus wild-type aS fibrils. We employed two well-characterized injection paradigms; intrahippocampal and intramuscular injection of aS fibrils (43) (44) (45) (46) . The use of M20 mice in the hippocampal injection experiment allows us to assess the abilities of the mutant aS fibrils to cross-seed wild-type aS, which is relevant to human disease as SNCA mutation carriers are heterozygous for the missense mutations. It would have been ideal to also use M20 mice for the muscle injection experiment, however, these mice do not develop robust aS inclusion pathology or motor impairment following this type of injection (46), making them unsuitable for this experiment. Therefore, we injected A53T aS transgenic (M83) mice, which have been extensively studied in the field, in the gastrocnemius muscle that has been previously shown to result in paralysis and CNS aS inclusion pathology (46) . Despite the introduction of another variable when using the M83 mice, we were still able to assess the abilities of the mutant aS fibrils to induce aS aggregation and paralysis relative to the wild-type protein.
In our peripheral injection study, the time from injection to paralysis was slightly but significantly shorter for H50Q, G51D and A53E aS compared with wild-type aS fibril injected mice, all of which became motor impaired within a very narrow time range, whereas paralysis of E46K aS fibril injected mice was significantly delayed, highly variable and not completely penetrant. The distributions of aS inclusions throughout the CNS of the paralyzed M83 mice were comparable between injection groups as these mice were all analyzed at endstage, and the 2 M83 mice injected with E46K aS fibrils that remained healthy showed no aS inclusions upon examination. The delayed, variable, and incomplete seeding following intramuscular inoculation of E46K aS fibrils in M83 mice shows that this mutant is less potent at inducing aS aggregation in these mice. These experiments demonstrate the unique characteristics of this mutant compared with the other aS mutants assessed, as well as wildtype aS, which is likely linked to the distinct structural properties of aggregated E46K aS polymers that has been observed using many different types of ultrastructural and biophysical methods (31) (32) (33) (34) 52, 53) . One of these studies showed that the E46K mutation enhances the contacts between the amino-and carboxy-terminal regions of aS (52), which might result in different conformers of aggregated aS within E46K aS polymerized fibrils.
Following hippocampal injection of aS fibrils (wild-type, H50Q, G51D and A53E), M20 mice were sacrificed at 2 and 4 month time points. These M20 mice showed similar patterns of aS pathology that progressed with time, spreading throughout the neuraxis. While all of these M20 mice displayed spread of aS inclusion pathology in the CNS, the relative amounts of aS inclusions slightly differed. G51D and H50Q aS fibril injected mice displayed more widespread inclusions compared with wild-type, and although A53E aS fibril injected mice displayed a similar pattern of aS inclusions to wild-type aS fibril injected mice at 2 months post-injection, these mice had a lower density of aS inclusions at the 4 month time-point.
As the A53E mutation has been reported to slow the rate of aS aggregation in vitro (29, 30) this provides a potential explanation for the reduction of aS pathology observed in the M20 mice injected in the hippocampus with A53E versus wild-type aS fibrils. In contrast, G51D was also shown to decrease aS fibril formation in vitro (26-28), however, induced more widespread aS inclusion pathology than wild-type aS fibrils at 2 months post-injection similar to that induced by H50Q aS fibrils, which was reported to accelerate fibril formation in vitro (22, 26, 27) . This suggests that the rate at which the mutant protein aggregates is not necessarily a critical driving factor in the seeded formation and spread of aS inclusions in vivo.
As Dhavale et al. recently reported that cross-seeding of mutant and wild-type aS results in a reduction of aggregation in vitro (27) , it would be expected to observe a reduction in the amount of aS inclusion pathology in the M20 mice injected with fibrillar aS mutants, if the in vitro findings were to predict outcomes in vivo. However, in the hippocampal injection of H50Q and G51D aS fibrils we observed more widespread aS inclusions compared with homotypic seeding, that being wild-type aS fibrils injected into M20 mice which express wild-type aS.
We also performed intrahippocampal injection of M20 mice with E46K aS fibrils, however, we analyzed these mice at later time points than the mice injected with the other mutant aS fibrils owing to the overall later onset of paralysis observed in the muscle injected M83 mice. Again, there was more variability in the induction of aS aggregation in the E46K aS fibril brain injected M20 mice, with only one out of the four mice showing any aS inclusions at 4 months post-injection, and which were restricted to the site of injection. Nevertheless, both sets of mice that were aged for 6 and 8 months post-injection displayed more aS inclusions upon analysis. These mice displayed spread of aS pathology to the thalamus and cortex at 6 months, and brainstem and spinal cord at 8 months post-injection. There also appeared to be some clearance of the aS inclusions over time, with one mouse at 6 months post-injection displaying no aS inclusions at the site of injection and one mouse at 8 months post-injection only displaying aS inclusions in the brainstem and spinal cord. These results suggest that E46K is the most inefficient of the tested mutants at inducing aS aggregation in vivo, despite its reported acceleration of aS fibrillization in vitro, in some cases (31) (32) (33) (34) . The inefficient induction of aS inclusion pathology by E46K aS preformed fibrillar seeds was also observed when directly injected in the brains of mice transgenic for human E46K aS (M47 line) (45) indicating that this property of the E46K mutant is not owing to heterologous protein incompatibility.
The discoveries of pathogenic aS missense mutations causal of neurodegeneration were seminal findings demonstrating the direct role of abnormal forms of aS in neuronal demise. However, synucleinopathies, even when associated with aS mutations, can present as a spectrum of clinical and pathological features, e.g. E46K mutation carriers often display REM sleep behavior disorder and dementia that are commonly seen in DLB patients (10, 54) and G51D mutation carriers may present with autonomic dysfunction, and glial cytoplasmic inclusions that are defining features of MSA (3, 19, 20) . We showed here that the effects of aS mutations on aggregation observed in vitro compared with the in vivo seeded induction of pathology can be divergent, such that a mutation that appears less prone to aggregate in vitro can still potently induce aggregation in seeded experimental paradigms in vivo. These differences might be explained by the many complex elements involved in the propagation of aS aggregates in vivo that include cellular uptake and release, relative stability of aggregated/misfolded aS, sequestration by cellular binding and efficiency in the recruitment of native aS protein by conformation templating. At this time, it is still unclear which of these steps is rate limiting in the in vivo spread of aS pathology, but these could be differentially affected for specific aS mutants, thus influencing the pathological and clinical presentations. The information derived from mutant forms of the aS protein may help to identify features of aS aggregation and propagation properties that could be potential targets for therapeutic intervention.
Materials and Methods

Recombinant aS expression, purification and fibril formation
The pRK172 bacterial expression vectors containing cDNA encoding wild-type, E46K, H50Q, G51D or A53E full-length human aS were generated as previously described (26, 30, 33, 55) . Plasmids were transformed into BL21 (DE3)/RIL Escherichia coli (E. coli; Agilent Technologies) and recombinant aS was purified from E. coli by size exclusion chromatography and subsequent Distribution maps of LS4-2G12 immunopositive aS staining in M20 mice at 2 months (A) and 4 months (B) post-intrahippocampal injection of human wildtype, H50Q, G51D or A53E aS fibrils (n ¼ 4-6 mice/group). anion exchange as previously described (33, 55) . Protein concentrations were determined by bicinchoninic acid assay using bovine serum albumin as the protein standard. Recombinant aS proteins (5 mg/ml in sterile PBS) were incubated at 37 C with constant shaking at 1050 rpm (Thermomixer R, Eppendorf) for >48 h. Fibril formation was monitored by K114 [(trans, trans)-1-bromo-2,5-bis-(4-hydroxy)styrylbenzene] fluorometry as previously described (56) . To prepare fibrils for injection, fibrils were diluted to 2 mg/ml in sterile PBS and sonicated in a water bath for 2 h. Sonicated fibrils were then aliquoted, stored at À80 C and thawed when required. Each experiment in this study was performed using fibrils from the same preparation, limiting batch to batch variation.
Mouse lines
All procedures were performed according to the National Institute of Health Guide for the Care and Use of Experimental Animals and were approved by the University of Florida
Institutional Animal Care and Use Committee. M20 and M83 mice on the C57BL/C3H background were previously described (47) . The M20 line is transgenic for wild-type aS and the M83 line is transgenic for aS with the pathogenic A53T mutation. All aS transgenic mice used in the studies were hemizygous.
Mouse injection procedures
For stereotaxic injection, hemizygous M20 mice (2-4 months of age) were anesthetized with 1-5% isoflurane and bilaterally injected in the hippocampus (coordinates from Bregma: anterior/ posterior À2.2 mm, lateral 61.6 mm, dorsal/ventral À1.2 mm) with 2 ll of mutant or wild-type aS fibrils (2 mg/ml) at a rate of 0.2 ll/min. Following injection, the needle was left in place for 5 min before removing. Mice were sacrificed at 2, 4, 6 or 8 months post-injection. For muscle injection, hemizygous M83 mice (2-3 months of age; n ¼ 10/group) were anesthetized with 1-5% isoflurane and bilaterally injected in the gastrocnemius muscle with 5 ll of aS fibrils (2 mg/ml). Muscle injected mice were sacrificed following the presentation of motor impairment that progressed to paralysis or at 375 days post injection, whichever came first.
Mice were humanely euthanized by CO 2 , followed by cardiac perfusion of PBS/heparin. Brain and spinal cord were harvested and fixed in 70% ethanol/150 mM NaCl. Tissues were dehydrated and embedded in paraffin, then cut into 5 lm sections using a microtome.
Antibodies
LS4-2G12 is a mouse monoclonal antibody that detects pSer129 aS (48) . Syn 211 is a mouse monoclonal antibody specific for human aS (57) and Syn 506 is a conformational anti-aS mouse monoclonal antibody that preferentially detects aS in pathological inclusions (58, 59) . Mouse monoclonal antibody 9C10 detects aS residues 2-21. Rabbit polyclonal antibody, p62 is a general inclusion marker (SQSTM1; Proteintech).
Immunohistochemistry
Sections were deparaffinized with xylene then rehydrated with a descending series of ethanols (100-70%). Sections underwent antigen retrieval in a 0.05% Tween-20 steam bath for 30 min then endogenous peroxidase activity was quenched with 1.5% hydrogen peroxide/0.005% Triton X-100/PBS for 20 min. Sections were blocked with 2% fetal bovine serum (FBS)/100 mM Tris, pH 7.6, and then incubated in primary antibody diluted in 2% FBS/ 100 mM Tris, pH 7.6 overnight at 4 C. The following day, sections were incubated in biotinylated horse anti-mouse or antirabbit secondary antibodies (Vector Laboratories) diluted in 2% FBS/100 mM Tris, pH 7.6 for 1 h at room temperature. Sections were then incubated in tertiary antibody (VECTASTAIN ABC kit, Vector Laboratories) diluted in 2% FBS/100 mM Tris, pH 7.6, for 1 h at room temperature and reactivity was visualized using the chromogen 3, 3'-diaminobenzidine. Sections were counterstained with Mayer's hematoxylin and dehydrated using an ascending series of ethanols (70-100%). Sections were cleared in xylene, coverslipped using cytoseal, and then scanned using an Aperio ScanScope CS (40Â magnification; Aperio Technologies Inc.).
Thioflavin S staining
After tissue sections were rehydrated as described above, sections were rinsed in PBS and then treated with Millipore autofluorescent agent (Millipore) for 5 min. Sections were washed three times in 40% ethanol/PBS and kept in the dark for all subsequent steps. Sections were incubated in 0.0125% Thioflavin S in 50% ethanol/PBS for 3 min and then washed in 50% ethanol/ PBS for 30 s. Following PBS washes, sections were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) and mounted using Fluoromount-G (Southern Biotech).
Campbell-Switzer silver stain
For silver staining, tissue sections were rehydrated as described above and developed with adapted Campbell-Switzer silver stain as previously described (49) .
Double immunofluorescence analysis
Tissue sections were deparaffinized and rehydrated, and antigen retrieval was performed as described in the immunohistochemistry methods. Sections were blocked with 5% dry milk/100 mM Tris pH 7.6. Primary antibodies were diluted in blocking solution and applied to sections for overnight incubation at 4 C. Sections were washed with 100 mM Tris pH 7.6 and secondary antibodies conjugated to Alexa Fluor 488 or 594 fluorophores (Life Technologies) were diluted in blocking solution and applied to sections for 2 h at room temperature in the dark. Sections were then treated with Sudan black to block lipofuscin autofluorescence. Nuclei were stained with DAPI (Pierce) and sections were mounted using Fluoromount-G (SouthernBiotech). Pictures were obtained using an Olympus BX51 fluorescent microscope mounted with a DP71 digital camera (Olympus) and images were overlaid using Photoshop software.
Quantification of staining and statistical analyses
Scanned images of LS4-2G12 stained sections were opened in ImageScope TM software (Leica Biosystems) and a single user blinded to conditions completed a distribution map (as shown in Figs 1, 3 and 5) for each mouse, which indicates the amount and location of LS4-2G12 positive inclusions. The distribution maps were decoded and averaged for each treatment. Mice within a group that showed disparate pathology were not included in the averaged distribution map and are noted in the results. Bar graphs and survival curves were plotted, and statistical analyses were performed in GraphPad Prism v5.03 software.
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